

# MEDICATIONS

## PHARMOKINETICS

\* STUDY OF ABSORPTION, DISTRIBUTION, METABOLISM, + EXCRETION (ADME) IN THE HUMAN BODY

\* KNOWLEDGE OF HOW MEDICATIONS WORK IN THE BODY, THEIR EFFECTS ON SPECIFIC ORGANS, THEIR INTENDED ACTIONS, + ADVERSE MED REACTIONS

**ABSORPTION:** MOVEMENT OF MEDICATION FROM WHERE IT WAS ADMINISTERED (ENTERS THE BODY), TO THE CIRCULATORY SYSTEM

\* AFFECTS THE SPEED + INTENSITY OF THE MEDS ACTION IN THE BODY

\* FACTORS AFFECTING RATE OF ABSORPTION:

- ROUTE OF ADMINISTRATION: POINT WHERE MED ENTERS BODY
- IONIZATION: THE PH OF MEDICATION + SITE OF ABSORPTION
- DISSOLUTION: MEDICATION MUST BE DISSOLVED BEFORE ABSORPTION HAPPENS
- BLOOD FLOW: MEDS ARE ABSORBED FASTER WHERE BLOOD FLOW IS HIGH
- LIPID SOLUBILITY: MED FORMULATION CAN EITHER HAVE HIGH OR LOW LIPID SOLUBILITY
- SURFACE AREA OF ABSORPTIVE SITE
- CLIENT SPECIFIC FACTORS: PATHOPHYSIOLOGICAL PROCESSES, DISEASE/INJURY, AGE, ETC


**DISTRIBUTION:** PROCESS TO THE TARGET ORGANS/TISSUES FOLLOWING ABSORPTION INTO CIRCULATORY SYSTEM

\* AFFECTED BY CLIENTS CIRCULATORY STATUS OR BLOOD FLOW + MEDS SOLUBILITY + PROTEIN BINDING ABILITY

◦ HIGHLY VASCULARIZED AREAS: RECEIVE GREATEST BLOOD SUPPLY

- heart
- liver
- brain
- kidney

◦ LOW VASCULARIZED AREAS: BONES, SKIN, ADIPOSE TISSUE



**METABOLISM (BIOTRANSFORMATION):** CHEMICAL PROCESS OF CONVERTING A MEDICATIONS STRUCTURE

\* CAN RESULT IN AMPLIFIED MEDICATION ACTIVITY, INACTIVATION OF MEDS, OR INCREASED EXCRETION VIA KIDNEYS, + CAN TOXICITY LEVELS OF MEDS

\* METABOLIZED PRIMARILY IN LIVER + KIDNEYS

◦ TRANSFORMED BY GROUP OF LIVER ENZYMES (CYTOCHROME P-450) TO ACTIVE + INACTIVE SUBSTANCES TO ALLOW FOR THEIR EXCRETION


◦ DIS W KIDNEY + LIVER DISEASE MAY HAVE SLOW RATE OF MEDICATION CLEARANCE

\* MAY TRANSFORM SPECIFIC MEDS TO ANOTHER FORM → MORE ACTIVE OR POTENT FORM

◦ CODEINE → MORPHINE RESULTING IN ↑ PAIN RELIEF

\* PRODRUGS: INACTIVE CHEMICALS THAT ARE ACTIVATED THROUGH METABOLISM TO EXERT THERAPEUTIC EFFECTS

\* FIRST PASS EFFECT:



CAN RESULT IN LOWER CONCENTRATION OF MEDICATION REACHING SYSTEMIC CIRCULATION, IF A MAJORITY OF THE MEDICATION HAS ALREADY BEEN METABOLIZED INTO AN INACTIVE FORM BEFORE IT ENTERS THE BLOOD STREAM

\* KNOWLEDGE IS CRUCIAL FOR DETERMINING APPROPRIATE ROUTE

\* CYP ENZYMES FOUND ON LIVER CELLS PLAY A ROLE ON MEDICATION METABOLISM

◦ BY REGULATING RATE AT WHICH A MEDICATION IS BROKEN DOWN + THE AMOUNT OF TIME MEDICATION STAYS IN BODY

\* NUTRIENTS CAN INFLUENCE MEDICATION METABOLISM

**EXCRETION:** PROCESS THAT MEDICATION IS REMOVED FROM BODY

\* KIDNEYS ARE PRIMARY ORGAN


\* RATE OF MED EXCRETION IS AFFECTED BY KIDNEY, HEART, + LIVER FUNCTION - INFLUENCE MED CONCENTRATION IN BODY

\* MEDICATION TOXICITY: WHEN BODY IS UNABLE TO METABOLIZE + EXCRETE A MED

◦ MAY CAUSE IRREVERSIBLE DAMAGE TO ORGANS

## Medication Preparation

- \* **pharmacodynamics**: study of how med works, its relationship to medication concentration, + how body responds (therapeutic range)
- \* **therapeutic drug monitoring (TDM)**: method used by health care providers to monitor medication concentration in pt blood
  - o Used for meds that have narrow therapeutic window - safe w/o causing adverse med reaction
- \* **peak and trough blood levels**: help maintain therapeutic med levels
  - o **peak blood levels**: when med is at highest concentration but below toxic level
    - o occur when absorption is complete
  - o **trough blood levels**: lowest level of concentration of med that correlates to rate of elimination
    - o measured before administering next scheduled dose
- \* **half-life**: time it takes for medication to fall to half its strength through excretion
  - o medications with longer half life may be administered once daily to maintain therapeutic level
    - o diazepam: half life 20-90 hours



## Adverse drug reactions

- \* **unintended + nontherapeutic effects** of medication - can range from tolerable to harmful
- \* **adverse drug event**: life threatening medication reaction that requires medical intervention to prevent death, permanent disability, congenital anomaly, or causes/prolongs hospitalization
  - o must be reported to FDA so agency can improve safety outcomes, revise labels + warnings, + withdraw med from market

## Allergic reactions

- \* When body perceives med as a foreign substance stimulating an immune response

## Anaphylaxis

- \* severe reaction in which immune response causes dyspnea, hypotension, + tachycardia
- \* **Steven-Johnson syndrome (SJS)**
  - o 1-14 days following administration
  - o respiratory distress, fever, chills, diffuse, fine rash, followed by blisters

## Medication interactions

- \* **drug-drug interactions**: effect that two or more drugs that pt is administered have on each other
  - o interactions may include intensifying the effects of one of the meds or decreasing effects of one of meds
- \* **drug-food interactions**: effects of nutrients on the ADME of medications
- \* **drug-herbal supplement interactions**: effects similar to drug-drug

## Factors affecting med actions

- \* **teratogenic**: medications that can cause fetal defects, pregnancy loss, prematurity or developmental disabilities
  - o cocaine
  - o ACE inhibitors
  - o alcohol
  - o gentamycin
  - o NSAIDs
  - o tetracycline